Ignite Creation Date:
2024-05-05 @ 4:58 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351832
Status:
COMPLETED
Last Update Posted:
2007-05-09
First Post:
2006-07-11
Brief Title:
A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Multicenter Double-Blind Randomized Parallel-Group Study to Compare the Effect of 12 Weeks Treatment With Vildagliptin 50mg qd 50mg Bid 100mg qd to Placebo in Patients With Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is not being conducted in the United States Vildagliptin is an oral antidiabetic agent This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None